Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Health Canada approves aflibercept biosimilar Aflivu

Health Canada approves aflibercept biosimilar Aflivu

Sydney M Crago
July 10th 2025
Article

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

A person sits at their laptop with a cup of coffee visible in the foreground. Concept image for instant coffee, AMD, age related macular degeneration, ocular health and instant coffee investigation. Image credit: ©Ljustina – stock.adobe.com

Patients with high genetic risk of AMD should avoid instant coffee, investigators say

Lynda Charters
July 1st 2025
Article

Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

Scientists work in a lab, looking at microscopes while data is superimposed over the top of the photo. Concept image for clinical trial research and structural functional endpoints in ophthalmology. Image credit: ©metamorworks – stock.adobe.com

Imaging the ellipsoid zone line could change the global approach to clinical trials

Hattie Hayes;Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
June 13th 2025
Article

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 5th 2025
Article

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

A bridge made from building blocks has an incomplete area. A hand reaches down with the missing block to close the gap. Concept image for age-related macular degeneration therapy and treatment article, IOL implantation and ophthalmology. Image credit: ©patpitchaya – stock.adobe.com

An implantable option bridges the gap for patients with AMD

Federico Badalà, MD
June 4th 2025
Article

Long-term benefits and vision preservation using an extended macular vision IOL

A pharmacist helps a customer access medication. Concept image for neovascular age-related macular degeneration eye drop treatment therapy. Image credit: ©Gorodenkoff – stock.adobe.com

Topline results from investigational nAMD drop SYL1801 (Sylentis)

Kassi Filkins
May 19th 2025
Article

Three dose level cohorts of the small interfering RNA therapeutic were evaluated in a double-blind study

© 2025 MJH Life Sciences

All rights reserved.